Aligos Therapeutics, Inc.(ALGS)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Aligos Therapeutics, Inc. (ALGS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ALGS at 4.6/100 on a 32-signal composite quality model, placing it at rank #2,955 of 2,962 stocks — the bottom half of the AI-ranked universe. Top institutional holders of ALGS by reported 13-F value include Deep Track Capital, Alyeska Investment Group, L.P., Sio Capital Management, based on the most recent SEC filings. ALGS trades on the Nasdaq exchange and files with the SEC under CIK 1799448. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ALGS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Aligos Therapeutics, Inc. directly from SEC EDGAR.